# A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

> **NCT05518253** · PHASE1 · RECRUITING · sponsor: **Weijia Fang, MD** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Tumor
- Advanced Solid Tumor
- Renal Cell Carcinoma
- Ovarian Cancer
- Cervix Cancer

## Interventions

- **BIOLOGICAL:** CD70 CAR-T cells
- **BIOLOGICAL:** CD70 CAR-T cells

## Key facts

- **NCT ID:** NCT05518253
- **Lead sponsor:** Weijia Fang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-30
- **Primary completion:** 2026-05-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05518253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05518253, "A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05518253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*